Advertisement

Acta Diabetologica

, Volume 55, Issue 7, pp 723–731 | Cite as

Characterization of circulating leukocytes and correlation of leukocyte subsets with metabolic parameters 1 and 5 years after diabetes diagnosis

  • Maria Apostolopoulou
  • Barbara Menart-Houtermans
  • Ruth Ruetter
  • Bettina Nowotny
  • Ulrich Gehrmann
  • Daniel Markgraf
  • Julia Szendroedi
  • Nanette C. Schloot
  • Michael Roden
Original Article

Abstract

Aims

Infiltration of pancreatic islets with different leukocyte subtypes likely contributes to deterioration of glycemia in diabetes mellitus. Different subsets of leukocytes have been previously associated with type 1 or type 2 diabetes. This study aimed at examining these subsets at different stages of diabetes progression and possible relationships with metabolic parameters.

Methods

A total of 206 patients, 76 with type 1 and 130 with type 2 diabetes, were studied within the first year of diabetes diagnosis. In addition, 31 patients with type 1 and 73 with type 2 diabetes were examined at 5 years after diagnosis. Whole body insulin sensitivity was assessed by hyperinsulinemic–euglycemic clamps; insulin secretion by glucagon stimulation tests and white blood cells were analyzed by flow cytometry.

Results

The percentage of peripheral CD8+ cells was 15% lower in patients with type 1 diabetes at 5 years than in patients at diabetes onset and correlated positively with fasting glycemia, total cholesterol and high-sensitive C-reactive protein (hsCRP) (all r > 0.37, p < 0.05), but not with insulin secretion. Patients with type 2 diabetes had 7% higher percentages of CD4+ cells after 5 years than those at diagnosis. CD4+ cells correlated with hsCRP (r = 0.36, p < 0.05), whereas CD8+ cytotoxic T-cells did not correlate with any metabolic parameter.

Conclusion

CD8+ T-cells associate with worse glycemia, lipidemia and inflammation after 5 years of type 1 diabetes, whereas CD4+ T-cells associate with increased inflammation after 5 years upon onset of type 2 diabetes.

Keywords

Leukocytes Diabetes progression Insulin secretion Insulin sensitivity 

Notes

Author contributions

MA researched data, calculated statistics and wrote the manuscript, BM-H and RR researched data, performed statistical calculations and reviewed the manuscript, BN and JS performed the clinical characterization of volunteers and reviewed the manuscript, UG provided advice for statistics and reviewed the manuscript, NCS and MR designed the study, contributed to data analysis and discussion and wrote, edited and reviewed the manuscript. NCS is currently employed by Lilly Germany. MR is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of data and the accuracy of the data analysis.

Funding

This work was supported by the Ministry of Science and Research of the State of North Rhine-Westphalia (MIWF NRW) and the German Federal Ministry of Health (BMG). This study was supported in part by a grant of the Federal Ministry for Research (BMBF) to the German Center for Diabetes Research (DZD e.V.), by grants of the Helmholtz Alliance Imaging and Curing Environmental Metabolic Diseases (ICEMED), the German Research Foundation (DFG, SFB1116, project B05) and by the Schmutzler-Stiftung. The funding sources had no input in the design and conduct of this study, in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the article.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest for this work.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Supplementary material

592_2018_1143_MOESM1_ESM.docx (144 kb)
Supplementary material 1 (DOCX 144 kb)

References

  1. 1.
    Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Prentki M, Nolan CJ (2006) Islet β cell failure in type 2 diabetes. J Clin Investig 116:1802–1812CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kaul K, Apostolopoulou M, Roden M (2015) Insulin resistance in type 1 diabetes mellitus. Metab Clin Exp 64:1629–1639CrossRefPubMedGoogle Scholar
  4. 4.
    Gepts W, In’t Veld PA (1987) Islet morphologic changes. Diabetes Metab Rev 3:859–872CrossRefPubMedGoogle Scholar
  5. 5.
    Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG (2014) Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes 63:3880–3890CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lundberg M, Seiron P, Ingvast S, Korsgren O, Skog O (2017) Insulitis in human diabetes: a histological evaluation of donor pancreases. Diabetologia 60:346–353CrossRefPubMedGoogle Scholar
  7. 7.
    Williams MD, Nadler JL (2007) Inflammatory mechanisms of diabetic complications. Curr Diabetes Rep 7:242–248CrossRefGoogle Scholar
  8. 8.
    Menart-Houtermans B, Rutter R, Nowotny B et al (2014) Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: results from the German Diabetes Study (GDS). Diabetes Care 37:2326–2333CrossRefPubMedGoogle Scholar
  9. 9.
    Sarikonda G, Pettus J, Phatak S et al (2014) CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun 50:77–82CrossRefPubMedGoogle Scholar
  10. 10.
    Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107CrossRefPubMedGoogle Scholar
  11. 11.
    Matveyenko AV, Butler PC (2008) Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab 10(Suppl 4):23–31CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143CrossRefPubMedGoogle Scholar
  13. 13.
    Brooks-Worrell BM, Boyko EJ, Palmer JP (2014) Impact of islet autoimmunity on the progressive beta-cell functional decline in type 2 diabetes. Diabetes Care 37:3286–3293CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA (2008) Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31(Suppl 2):S161–S164CrossRefPubMedGoogle Scholar
  15. 15.
    Szendroedi J, Saxena A, Weber KS et al (2016) Cohort profile: the German Diabetes Study (GDS). Cardiovasc Diabetol 15:59CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966–1971CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chung FM, Tsai JC, Chang DM, Shin SJ, Lee YJ (2005) Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis. Diabetes Care 28:1710–1717CrossRefPubMedGoogle Scholar
  18. 18.
    Pertynska-Marczewska M, Kiriakidis S, Wait R, Beech J, Feldmann M, Paleolog EM (2004) Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine 28:35–47CrossRefPubMedGoogle Scholar
  19. 19.
    Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8:709–716CrossRefPubMedGoogle Scholar
  20. 20.
    McLaughlin T, Liu LF, Lamendola C et al (2014) T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol 34:2637–2643CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Valle A, Giamporcaro GM, Scavini M et al (2013) Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 62:2072–2077CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8:301–309CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2):S97–107CrossRefPubMedGoogle Scholar
  24. 24.
    Coppieters KT, Dotta F, Amirian N et al (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209:51–60CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, Kammoun Héè L (2014) Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? Front Immunol 5:470CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Zeyda M, Farmer D, Todoric J et al (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (2005) 31:1420–1428CrossRefGoogle Scholar
  27. 27.
    Dworacka M, Wesolowska A, Wysocka E, Winiarska H, Iskakova S, Dworacki G (2014) Circulating CD3+56+ cell subset in pre-diabetes. Exp Clin Endocrinol Diabetes Off J Germ Soc Endocrinol Germ Diabetes Assoc 122:65–70Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Maria Apostolopoulou
    • 1
    • 2
    • 3
  • Barbara Menart-Houtermans
    • 2
    • 3
  • Ruth Ruetter
    • 2
    • 3
  • Bettina Nowotny
    • 2
    • 3
  • Ulrich Gehrmann
    • 3
    • 4
  • Daniel Markgraf
    • 2
    • 3
  • Julia Szendroedi
    • 1
    • 2
    • 3
  • Nanette C. Schloot
    • 2
  • Michael Roden
    • 1
    • 2
    • 3
  1. 1.Division of Endocrinology and Diabetology, Medical Faculty, c/o German Diabetes CenterHeinrich-Heine University, DüsseldorfDüsseldorfGermany
  2. 2.Institute for Clinical Diabetology, German Diabetes CenterLeibniz Center for Diabetes Research at Heinrich-Heine University DüsseldorfDüsseldorfGermany
  3. 3.German Center for Diabetes ResearchDüsseldorfGermany
  4. 4.Institute for Biometrics and Epidemiology, German Diabetes CenterLeibniz Center for Diabetes Research at Heinrich-Heine UniversityDüsseldorfGermany

Personalised recommendations